Vangenes Biotech Group, established in 2013, is an international biotechnology company headquartered in Xiamen City, China, with branches in the United States, Brazil and Chinese Hong Kong. We have NGS laboratories in China and the United States. We are committed to non-invasive pan-cancer early screening, non-invasive prenatal paternity testing, personal genome. We have rich scientific research experience, advanced technology platform and excellent expert team.

We have successfully applied the NGS technology and bioinformatics analysis technology to the field of genetic testing. We have non-invasive multi-cancer early screening technology (3 cancer types: lung cancer, liver cancer, breast cancer), non-invasive prenatal paternity testing technology, non-invasive Down's screening technology.

Our Service in Asia Pacific

Our Science Research Articles

• An adaptive detection method for fetal chromosomal aneuploidy using cell-free DNA from 447 Korean women

Sunshin Kim, HeeJung Jung, Sung Hee Han, SeungJae Lee, JeongSub Kwon, Min Gyun Kim, Hyungsik Chu, Kyudong Han, Hwanjong Kwak, Sunghoon Park, Hee Jae Joo, Minae An, Jungsu Ha, Kyusang Lee, Byung Chul Kim, Hailing Zheng, Xinqiang Zhu, Hongliang Chen, Jong Bhak

BMC Med Genomics. 2016; 9: 61. Published online 2016 Oct 3. doi: 10.1186/s12920-016-0222-5

PMCID: PMC5048604

• Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy

Sunshin Kim, HeeJung Jung, Sung Hee Han, SeungJae Lee, JeongSub Kwon, Min Gyun Kim, Hyungsik Chu, Hongliang Chen, Kyudong Han, Hwanjong Kwak, Sunghoon Park, Hee Jae Joo, Byung Chul Kim, Jong Bhak

BMC Med Genomics. 2016; 9: 22. Published online 2016 Apr 30. doi: 10.1186/s12920-016-0182-9

PMCID: PMC4851803

• The Feasibility Study of Non-Invasive Fetal Trisomy 18 and 21 Detection with Semiconductor Sequencing Platform

Young Joo Jeon, Yulin Zhou, Yihan Li, Qiwei Guo, Jinchun Chen, Shengmao Quan, Ahong Zhang, Hailing Zheng, Xingqiang Zhu, Jin Lin, Huan Xu, Ayang Wu, Sin-Gi Park, Byung Chul Kim, Hee Jae Joo, Hongliang Chen, Jong Bhak

PLoS One. 2014; 9(10): e110240. Published online 2014 Oct 20. doi: 10.1371/journal.pone.0110240

PMCID: PMC4203771

• Hepatocellular carcinoma detection via targeted enzymatic methyl sequencing of plasma cell-free DNA

Ping Guo, Hailing Zheng, Yihan Li, Yuntong Li, Yue Xiao, Jin Zheng, Xingqiang Zhu, Huan Xu, Zhi He, Qian Zhang, Jinchun Chen, Mingshan Qiu, Min Jiang, Pingguo Liu, Hongliang Chen

Clin Epigenetics. 2023; 15: 2. Published online 2023 Jan 4. doi: 10.1186/s13148-022-01420-6

PMCID: PMC9814445

Our Intellectual Patents

• Method for eliminating GC bias caused by high-throughput sequencing and detecting chromosome copy number mutation (patent No. ZL201410394930.X)

Through comparing and correcting the gene sequence obtained by processing the human genome using high-throughput sequencing technology, this method performs a T test between chromosomes to determine whether there is euploid variation in the chromosome in the mixed sample.

This patent well solves the technical problem of GC bias caused by high-throughput sequencing, thus making it possible to apply high-throughput sequencing in the detection of chromosome copy number variation in mixed samples.

• Quantitative method for free fetal DNA (deoxyribonucleic acid) proportion in maternal peripheral blood (patent number ZL201510225771.5)

The invention discloses a quantitative method for free fetal DNA (deoxyribonucleic acid) proportion in maternal peripheral blood. DNA containing designed SNP (single nucleotide polymorphism) in plasma is extracted by the aid of a designed primer and loaded on a machine after a series of treatment, sequencing products are compared to a human genome sequence, and a basic group of each SNP site is determined. The concentration of the free fetal DNA is quantified by analyzing the proportion of the basic groups in the SNP. Induced errors can be corrected by the aid of a plurality of SNP sites, the SNP sites are simultaneously calculated by a statistics method, and calculated free fetal DNA concentration accuracy is improved.

• Method for judging antenatal parental right relation with SNP (patent number ZL201510390373.9)

The invention provides a method for judging antenatal parental right relation with SNP. The SNP is used as a genetic marker, and judgment of the antenatal parental right relation is conducted through cooperation of the SNP and the high throughput sequencing technology. Only 10 ml of maternal peripheral blood is needed, free DNA extracted from the maternal peripheral blood plasma contains the free DNA of a fetus already, so that only one sample of a mother and the fetus is needed. Due to the fact that only the venous blood of a pregnant woman needs to be extracted, operation is simple and convenient, the pregnant woman and the fetus cannot be damaged.